Ballentine Partners LLC lifted its holdings in shares of AbbVie Inc (NYSE:ABBV) by 9.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,525 shares of the company’s stock after acquiring an additional 770 shares during the quarter. Ballentine Partners LLC’s holdings in AbbVie were worth $806,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in the stock. Signature Estate & Investment Advisors LLC purchased a new stake in AbbVie in the third quarter worth $112,000. First Mercantile Trust Co. purchased a new stake in AbbVie in the second quarter worth $150,000. MUFG Securities EMEA plc purchased a new stake in AbbVie in the second quarter worth $157,000. Kiley Juergens Wealth Management LLC grew its stake in AbbVie by 69.3% in the third quarter. Kiley Juergens Wealth Management LLC now owns 1,761 shares of the company’s stock worth $166,000 after purchasing an additional 721 shares during the period. Finally, S. R. Schill & Associates purchased a new stake in AbbVie in the second quarter worth $200,000. Institutional investors own 69.85% of the company’s stock.

In other AbbVie news, EVP Henry O. Gosebruch sold 42,450 shares of the stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $90.10, for a total value of $3,824,745.00. Following the transaction, the executive vice president now owns 30,350 shares of the company’s stock, valued at $2,734,535. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.07% of the stock is currently owned by corporate insiders.

ABBV stock opened at $90.33 on Friday. AbbVie Inc has a fifty-two week low of $77.50 and a fifty-two week high of $125.86. The company has a debt-to-equity ratio of 8.70, a quick ratio of 1.08 and a current ratio of 1.20. The stock has a market capitalization of $136.21 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 0.84 and a beta of 1.68.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, November 2nd. The company reported $2.14 earnings per share for the quarter, beating analysts’ consensus estimates of $2.01 by $0.13. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. The company had revenue of $8.24 billion for the quarter, compared to the consensus estimate of $8.23 billion. During the same quarter in the prior year, the company earned $1.41 earnings per share. AbbVie’s revenue was up 17.7% on a year-over-year basis. On average, equities analysts predict that AbbVie Inc will post 7.93 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 15th. Shareholders of record on Tuesday, January 15th will be issued a $1.07 dividend. This is an increase from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. This represents a $4.28 dividend on an annualized basis and a yield of 4.74%. AbbVie’s dividend payout ratio is currently 68.57%.

A number of equities research analysts have recently commented on the company. Credit Suisse Group set a $85.00 target price on AbbVie and gave the stock a “sell” rating in a research note on Saturday, October 20th. BMO Capital Markets cut their target price on AbbVie from $78.00 to $71.00 and set an “underperform” rating on the stock in a research note on Monday, November 5th. SunTrust Banks cut their target price on AbbVie from $157.00 to $135.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. ValuEngine raised AbbVie from a “sell” rating to a “hold” rating in a research note on Monday, November 12th. Finally, Argus cut their target price on AbbVie from $130.00 to $115.00 and set a “buy” rating on the stock in a research note on Tuesday, November 6th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $103.68.

ILLEGAL ACTIVITY NOTICE: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/abbvie-inc-abbv-position-boosted-by-ballentine-partners-llc/2666460.html.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.

Recommended Story: NASDAQ

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.